View Item 

Show simple item record

Diagnosis and Management of Antibody‐Mediated Rejection: Current Status and Novel Approaches
dc.contributor.authorDjamali, A.en_US
dc.contributor.authorKaufman, D. B.en_US
dc.contributor.authorEllis, T. M.en_US
dc.contributor.authorZhong, W.en_US
dc.contributor.authorMatas, A.en_US
dc.contributor.authorSamaniego, M.en_US
dc.date.accessioned2014-02-11T17:56:59Z
dc.date.available2015-04-01T19:59:06Zen_US
dc.date.issued2014-02en_US
dc.identifier.citationDjamali, A.; Kaufman, D. B.; Ellis, T. M.; Zhong, W.; Matas, A.; Samaniego, M. (2014). "Diagnosis and Management of Antibody‐Mediated Rejection: Current Status and Novel Approaches." American Journal of Transplantation 14(2): 255-271.en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/102649
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherAntibody‐Mediated Rejectionen_US
dc.subject.otherDonor‐Specific Antibodiesen_US
dc.subject.otherPhenotypeen_US
dc.subject.otherComplement C4den_US
dc.titleDiagnosis and Management of Antibody‐Mediated Rejection: Current Status and Novel Approachesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/102649/1/ajt12589.pdf
dc.identifier.doi10.1111/ajt.12589en_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceVo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost‐effectiveness of desensitization using IVIG and rituximab. Transplantation 2013; 95: 852 – 858.en_US
dc.identifier.citedreferenceFranco A, Anaya F, Niembro E, Ahijado F, Luño J, Valderrábano F. Plasma exchange in the treatment of vascular rejection: Relationship between histological changes and therapeutic response. Transplant Proc 1987; 19: 3661 – 3663.en_US
dc.identifier.citedreferenceLefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti‐CD20 versus high‐dose IVIg in the treatment of antibody‐mediated rejection. Am J Transplant 2009; 9: 1099 – 1107.en_US
dc.identifier.citedreferenceKaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63 – 73.en_US
dc.identifier.citedreferenceVangelista A, Frasca GM, Nanni Costa A, Stefoni S, Bonomini V. Value of plasma exchange in renal transplant rejection induced by specific anti‐HLA antibodies. Trans Am Soc Artif Intern Organs 1982; 28: 599 – 603.en_US
dc.identifier.citedreferenceMacaluso J, Killackey M, Paramesh A, et al. Comparative study of bortezomib therapy for antibody mediated rejection. Am J Transplant 2011; 11 (Suppl 2, Abstract #431): 160.en_US
dc.identifier.citedreferenceLubetzky ML, Walker JK, Matignon M, et al. Evolving therapies for antibody mediated rejection: Is bortezomib better than rituximab [abstract SA‐PO3065]. World Congress of Nephrology 2011. Vancouver, Canada; 2011.en_US
dc.identifier.citedreferenceWaiser J, Schutz M, Liefeldt L, Schonemann C, Neumayer H‐H, Budde K. Treatment of antibody‐mediated renal allograft rejection with bortezomib or rituximab. Am J Transplant 2010; 10 (Suppl 4, Abstract #1504): 466.en_US
dc.identifier.citedreferenceSautenet B, Blancho G, Buchler M, et al. One year results of the effects of rituximab on acute humoral rejection in renal transplantation: RITUX ERAH, a multicenter randomized placebo controlled trial. Am J Transplant 2013; 13 (Suppl 5, Abstract #266): 112.en_US
dc.identifier.citedreferenceLocke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody‐mediated rejection. Am J Transplant 2009; 9: 231 – 235.en_US
dc.identifier.citedreferenceKidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1 – S155.en_US
dc.identifier.citedreferenceFehr T, Gaspert A. Antibody‐mediated kidney allograft rejection: Therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623 – 632.en_US
dc.identifier.citedreferenceSmith RN, Malik F, Goes N, et al. Partial therapeutic response to rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 2012; 27: 107 – 113.en_US
dc.identifier.citedreferenceClatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359 – 1367.en_US
dc.identifier.citedreferenceSato Y, Sahara H, Tsukahara T, et al. Improved generation of HLA class I/peptide tetramers. J Immunol Methods 2002; 271: 177 – 184.en_US
dc.identifier.citedreferenceChen J, Yin H, Xu J, et al. Reversing endogenous alloreactive B cell GC responses with anti‐CD154 or CTLA‐4Ig. Am J Transplant 2013; 13: 2280 – 2292.en_US
dc.identifier.citedreferenceHeidt S, Hester J, Shankar S, Friend PJ, Wood KJ. B cell repopulation after alemtuzumab induction‐transient increase in transitional B cells and long‐term dominance of naïve B cells. Am J Transplant 2012; 12: 1784 – 1792.en_US
dc.identifier.citedreferenceWillicombe M, Roufosse C, Brookes P, et al. Antibody‐mediated rejection after alemtuzumab induction: Incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92: 176 – 182.en_US
dc.identifier.citedreferenceKnechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 2009; 9: 1087 – 1098.en_US
dc.identifier.citedreferenceMartin ST, Tichy EM, Gabardi S. Belatacept: A novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011; 31: 394 – 407.en_US
dc.identifier.citedreferenceLemy A, Toungouz M, Abramowicz D. Bortezomib: A new player in pre‐ and post‐transplant desensitization ? Nephrol Dial Transplant 2010; 25: 3480 – 3489.en_US
dc.identifier.citedreferencePuttarajappa C, Shapiro R, Tan HP. Antibody‐mediated rejection in kidney transplantation: A review. J Transplant 2012; 2012: 193724.en_US
dc.identifier.citedreferenceWebber A. Update on treatment options for antibody‐mediated rejection [oral presentation]. Presented at UCSF Transplant Symposium, San Francisco, CA; 2012, September 27–28. Available at: http://www.ucsfcme.com/2012/slides/MMC13001/12.%20Allison%20Webber.pdf. Accessed July 31, 2013.en_US
dc.identifier.citedreferenceColl E, Crespo M, Solé M, et al. Lessons from cyclosporine monotherapy in renal transplantation: The impact of acute rejection on long‐term allograft outcome. Transplant Proc 2004; 36 (Suppl): S114 – S116.en_US
dc.identifier.citedreferenceHariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605 – 612.en_US
dc.identifier.citedreferenceMeier‐Kriesche HJ, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378 – 383.en_US
dc.identifier.citedreferenceMeier‐Kriesche HU, Schold JD, Kaplan B. Long‐term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies ? Am J Transplant 2004; 4: 1289 – 1295.en_US
dc.identifier.citedreferenceLamb KE, Lodhi S, Meier‐Kriesche HU. Long‐term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450 – 462.en_US
dc.identifier.citedreferenceOrgan Procurement and Transplant Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR). 2011 Annual Report. Available at: http://www.srtr.org/annual_reports/. Accessed June 3, 2013.en_US
dc.identifier.citedreferenceDjamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 2006; 1: 623 – 640.en_US
dc.identifier.citedreferenceHalloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715 – 2729.en_US
dc.identifier.citedreferenceLarsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T‐cell costimulation: A therapeutic strategy for long‐term maintenance immunosuppression. Am J Transplant 2006; 6 ( 5 Pt 1 ): 876 – 883.en_US
dc.identifier.citedreferenceJordan SC, Pescovitz MD. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421 – 432.en_US
dc.identifier.citedreferenceStegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high‐dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346 – 351.en_US
dc.identifier.citedreferenceEl‐Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527 – 535.en_US
dc.identifier.citedreferenceSellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody‐mediated rejection and nonadherence. Am J Transplant 2012; 12: 388 – 399.en_US
dc.identifier.citedreferenceWiebe C, Gibson IW, Blydt‐Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor‐specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157 – 1167.en_US
dc.identifier.citedreferenceFarkash EA, Colvin RB. Diagnostic challenges in chronic antibody‐mediated rejection. Nat Rev Nephrol 2012; 8: 255 – 257.en_US
dc.identifier.citedreferenceSis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d‐negative antibody‐mediated rejection. Curr Opin Organ Transplant 2010; 15: 42 – 48.en_US
dc.identifier.citedreferenceHidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor‐specific antibodies: Evidence for NK cell involvement in antibody‐mediated rejection. Am J Transplant 2010; 10: 1812 – 1822.en_US
dc.identifier.citedreferenceDrachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody‐mediated allograft rejection: A schematic view based on pathogenesis. Transplantation 2013; 95: 1073 – 1083.en_US
dc.identifier.citedreferenceLynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL. Cryptic B cell response to renal transplantation. Am J Transplant 2013; 13: 1713 – 1723.en_US
dc.identifier.citedreferenceCascalho MI, Chen BJ, Kain M, Platt JL. The paradoxical functions of B cells and antibodies in transplantation. J Immunol 2013; 190: 875 – 879.en_US
dc.identifier.citedreferenceMengel M, Sis B, Haas M, et al. Banff 2011 meeting report: New concepts in antibody‐mediated rejection. Am J Transplant 2012; 12: 563 – 570.en_US
dc.identifier.citedreferenceHalloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti‐class I antibody response: I. Clinical and pathologic features of anti‐class I‐mediated rejection. Transplantation 1990; 49: 85 – 91.en_US
dc.identifier.citedreferenceHalloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti‐class I response: II. Clinical and pathologic features of renal transplants with anti‐class I‐like antibody. Transplantation 1992; 53: 550 – 555.en_US
dc.identifier.citedreferenceFeucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333 – 1338.en_US
dc.identifier.citedreferenceCollins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208 – 2214.en_US
dc.identifier.citedreferenceMauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody‐mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574 – 582.en_US
dc.identifier.citedreferenceRegele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371 – 2380.en_US
dc.identifier.citedreferenceSis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464 – 471.en_US
dc.identifier.citedreferenceRacusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562 – 1566.en_US
dc.identifier.citedreferenceHaas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d‐negative antibody‐mediated rejection and antibody‐associated arterial lesions. Am J Transplant 2014; 14: 272 – 283.en_US
dc.identifier.citedreferenceCohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628 – 639.en_US
dc.identifier.citedreferenceHaas M. C4d‐negative antibody‐mediated rejection in renal allografts: Evidence for its existence and effect on graft survival. Clin Nephrol 2011; 75: 271 – 278.en_US
dc.identifier.citedreferenceLoupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor‐specific antibodies (DSA). Am J Transplant 2011; 11: 56 – 65.en_US
dc.identifier.citedreferenceSis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody‐mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312 – 2323.en_US
dc.identifier.citedreferenceEinecke G, Sis B, Reeve J, et al. Antibody‐mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520 – 2531.en_US
dc.identifier.citedreferenceSellarés J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody‐mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971 – 983.en_US
dc.identifier.citedreferenceOpelz G, Collaborative Transplant Study. Non‐HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570 – 1576.en_US
dc.identifier.citedreferenceBenichou G, Yamada Y, Aoyama A, Madsen JC. Natural killer cells in rejection and tolerance of solid organ allografts. Curr Opin Organ Transplant 2011; 16: 47 – 53.en_US
dc.identifier.citedreferenceMorris PJ, Williams GM, Hume DM, Mickey MR, Terasaki PI. Serotyping for homotransplantation: XII. Occurrence of cytotoxic antibodies following kidney transplantation in man. Transplantation 1968; 6: 392 – 399.en_US
dc.identifier.citedreferenceMcKenna RM, Takemoto SK, Terasaki PI. Anti‐HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319 – 326.en_US
dc.identifier.citedreferenceZou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney‐transplant rejection. N Engl J Med 2007; 357: 1293 – 1300.en_US
dc.identifier.citedreferenceDunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132 – 2143.en_US
dc.identifier.citedreferenceGloor JM, Winters JL, Cornell LD, et al. Baseline donor‐specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582 – 589.en_US
dc.identifier.citedreferenceLefaucheur C, Antoine C, Suberbielle C, Glotz D. Mastering the risk of HLA antibodies in kidney transplantation: An algorithm based on pretransplant single‐antigen flow bead techniques. Am J Transplant 2011; 11: 1592 – 1598.en_US
dc.identifier.citedreferenceLoupy A, Lefaucheur C, Vernerey D, et al. Outcome and therapeutic approaches in acute rejection with vascular lesions and DSAs. Am J Transplant 2011; 11 (Suppl 2, Abstract #546): 193.en_US
dc.identifier.citedreferenceMohan S, Palanisamy A, Tsapepas D, et al. Donor‐specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23: 2061 – 2071.en_US
dc.identifier.citedreferenceNiederhaus SV, Muth B, Lorentzen DF, et al. Luminex‐based desensitization protocols: The University of Wisconsin initial experience. Transplantation 2011; 92: 12 – 17.en_US
dc.identifier.citedreferenceDjamali A, Muth B, Ellis TM, et al. Increased C4d in post‐reperfusion biopsies and increased donor specific antibodies at one‐week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int 2013; 83: 1185 – 1192.en_US
dc.identifier.citedreferenceSingh N, Djamali A, Lorentzen D, et al. Pretransplant donor‐specific antibodies detected by single‐antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079 – 1084.en_US
dc.identifier.citedreferenceCampos EF, Tedesco‐Silva H, Machado PG, Franco M, Medina‐Pestana JO, Gerbase‐DeLima M. Post‐transplant anti‐HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316 – 2320.en_US
dc.identifier.citedreferenceBentall A, Cornell LD, Gloor JM, et al. Five‐year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76 – 85.en_US
dc.identifier.citedreferenceZhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459 – 2465.en_US
dc.identifier.citedreferenceValenzuela NM, Hong L, Shen XD, et al. Blockade of p‐selectin is sufficient to reduce MHC I antibody‐elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13: 299 – 311.en_US
dc.identifier.citedreferenceArchdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody‐mediated rejection workshop. Am J Transplant 2011; 11: 896 – 906.en_US
dc.identifier.citedreferenceLefaucheur C, Loupy A, Hill GS, et al. Preexisting donor‐specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398 – 1406.en_US
dc.identifier.citedreferenceTyan DB. New approaches for detecting complement‐fixing antibodies. Curr Opin Organ Transplant 2012; 17: 409 – 415.en_US
dc.identifier.citedreferenceGebel HM, Bray RA. The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Nephrol Hypertens 2010; 19: 598 – 602.en_US
dc.identifier.citedreferenceTait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non‐HLA antibodies in transplantation. Transplantation 2013; 95: 19 – 47.en_US
dc.identifier.citedreferenceHalloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223 – 2230.en_US
dc.identifier.citedreferenceGaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody‐mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68 – 74.en_US
dc.identifier.citedreferenceEverly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor‐specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063 – 1071.en_US
dc.identifier.citedreferenceLederer SR, Kluth‐Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long‐term survival of renal allografts. Kidney Int 2001; 59: 334 – 341.en_US
dc.identifier.citedreferenceHidalgo LG, Campbell PM, Sis B, et al. De novo donor‐specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532 – 2541.en_US
dc.identifier.citedreferencePoduval RD, Kadambi PV, Josephson MA, et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation 2005; 79: 228 – 235.en_US
dc.identifier.citedreferenceKedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donor‐specific antibodies and decreased allograft survival. Am J Transplant 2009; 9: 812 – 819.en_US
dc.identifier.citedreferenceDragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1‐receptor activating antibodies in renal‐allograft rejection. N Engl J Med 2005; 352: 558 – 569.en_US
dc.identifier.citedreferenceMartin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor‐specific anti‐HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395 – 400.en_US
dc.identifier.citedreferenceVidard L, Kovacsovics‐Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 1996; 156: 2809 – 2818.en_US
dc.identifier.citedreferenceLoupy A, Suberbielle‐Boissel C, Hill GS, et al. Outcome of subclinical antibody‐mediated rejection in kidney transplant recipients with preformed donor‐specific antibodies. Am J Transplant 2009; 9: 2561 – 2570.en_US
dc.identifier.citedreferenceHaas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody‐mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576 – 585.en_US
dc.identifier.citedreferenceGloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124 – 2132.en_US
dc.identifier.citedreferenceSis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody‐mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168 – 1179.en_US
dc.identifier.citedreferenceBen‐Dov IZ, Muthukumar T, Morozov P, Mueller FB, Tuschl T, Suthanthiran M. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012; 94: 1086 – 1094.en_US
dc.identifier.citedreferenceFreitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin‐G subclasses and C1q in de novo HLA‐DQ donor‐specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113 – 1119.en_US
dc.identifier.citedreferenceSutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12 – 17.en_US
dc.identifier.citedreferenceYabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q‐fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342 – 347.en_US
dc.identifier.citedreferenceOtten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD. Pretransplant donor‐specific HLA class‐I and ‐II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2007; 7: 2809 – 2815.en_US
dc.identifier.citedreferenceSmith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies—A new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809 – 2815.en_US
dc.identifier.citedreferenceWahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d‐fixing and non‐C4d‐fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982 – 989.en_US
dc.identifier.citedreferenceBlume OR, Yost SE, Kaplan B. Antibody‐mediated rejection: Pathogenesis, prevention, treatment, and outcomes. J Transplant 2012; 2012: 201754.en_US
dc.identifier.citedreferenceAmico P, Hönger G, Steiger J, Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 656 – 661.en_US
dc.identifier.citedreferenceBingaman AW, Murphey CL, Palma‐Vargas J, Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864 – 1868.en_US
dc.identifier.citedreferenceMorath C, Opelz G, Zeier M, Süsal C. Prevention of antibody‐mediated kidney transplant rejection. Transpl Int 2012; 25: 633 – 645.en_US
dc.identifier.citedreferenceClaas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190 – 193.en_US
dc.identifier.citedreferenceJordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end‐stage renal disease: Report of the NIH‐IG02 trial. J Am Soc Nephrol 2004; 15: 3256 – 3262.en_US
dc.identifier.citedreferenceVo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242 – 251.en_US
dc.identifier.citedreferenceAlachkar N, Lonze BE, Zachary AA, et al. Infusion of high‐dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165 – 171.en_US
dc.identifier.citedreferenceKozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time ? Ann Transplant 2011; 16: 19 – 25.en_US
dc.identifier.citedreferenceMarfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94: 345 – 351.en_US
dc.identifier.citedreferenceNoel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high‐immunological‐risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385 – 1392.en_US
dc.identifier.citedreferenceThibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998; 13: 711 – 715.en_US
dc.identifier.citedreferenceMako M, Hager D, Muth B, Kaufman D, Ellis T, Djamali A. Thymoglobulin is associated with a significant reduction in de novo donor‐specific antibodies and antibody mediated rejection in moderately sensitized renal transplant recipients. Am J Transplant 2013; 13 (Suppl 5, Abstract #265): 113.en_US
dc.identifier.citedreferenceChandraker A, Guleria I, Ikle D, et al. Development of de novo anti‐HLA abs in kidney transplant recipients: Final analysis of the NIH CTOT02 study. Am J Transplant 2013; 13 (Suppl 5, Abstract #268): 113.en_US
dc.identifier.citedreferenceHarmon W, Guleria I, Ikle D, et al. Children develop de novo anti‐HLA antibodies (Abs) following kidney transplantation at a higher incidence than adults: An analysis of the NIH CTOT/CCTPT‐02 study. Am J Transplant 2013; 13 (Suppl 5, Abstract #21): 36 – 337.en_US
dc.identifier.citedreferenceMontgomery RA, Lonze BE, King KE, et al. Desensitization in HLA‐incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318 – 326.en_US
dc.identifier.citedreferenceHaririan A, Nogueira J, Kukuruga D, et al. Positive cross‐match living donor kidney transplantation: Longer‐term outcomes. Am J Transplant 2009; 9: 536 – 542.en_US
dc.identifier.citedreferenceMorgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: A systematic review and meta‐analysis. Transplantation 2012; 93: 1179 – 1188.en_US
dc.identifier.citedreferenceLü TM, Yang SL, Wu WZ, Tan JM. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chin Med J (Engl) 2011; 124: 664 – 668.en_US
dc.identifier.citedreferenceHanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909 – 1919.en_US
dc.identifier.citedreferenceKnechtle SJ, Pirsch JD, H Fechner J, et al. Campath‐1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722 – 730.en_US
dc.identifier.citedreferenceBloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9: 1835 – 1845.en_US
dc.identifier.citedreferenceTodeschini M, Cortinovis M, Perico N, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low‐dose rabbit anti‐thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor‐specific anti‐HLA antibody development. J Immunol 2013; 191: 2818 – 2828.en_US
dc.identifier.citedreferenceBarnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int 2013; 26: 563 – 575.en_US
dc.identifier.citedreferencevan den Hoogen M, Steenbergen E, Hoitsma A, Hilbrands L. Rituximab to prevent renal allograft rejection; a randomized, double‐blind, placebo‐controlled trial. Am J Transplant 2013; 13 (Suppl 5, Abstract #266.1): 112.en_US
dc.identifier.citedreferenceKohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody‐mediated rejection is reduced by targeting B‐cell immunity during an introductory period. Am J Transplant 2012; 12: 469 – 476.en_US
dc.identifier.citedreferenceEverly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody‐ and cell‐mediated acute rejection. Transplantation 2008; 86: 1754 – 1761.en_US
dc.identifier.citedreferenceEverly MJ, Everly JJ, Terasaki PI. Role of proteasome inhibition in sensitized transplant candidates. Chin Med J (Engl) 2011; 124: 771 – 774.en_US
dc.identifier.citedreferenceEverly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor‐based therapy. Transplantation 2012; 93: 572 – 577.en_US
dc.identifier.citedreferenceStegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody‐mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405 – 2413.en_US
dc.identifier.citedreferenceClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available at: http://www.clinicaltrials.gov/. Accessed June 3, 2013.en_US
dc.identifier.citedreferenceMelcher ML, Leeser DB, Gritsch HA, et al. Chain transplantation: Initial experience of a large multicenter program. Am J Transplant 2012; 12: 2429 – 2436.en_US
dc.identifier.citedreferenceRoodnat JI, Kal‐van Gestel JA, Zuidema W, et al. Successful expansion of the living donor pool by alternative living donation programs. Am J Transplant 2009; 9: 2150 – 2156.en_US
dc.identifier.citedreferenceSegev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA. JAMA 2005; 293: 1883 – 1890.en_US
dc.identifier.citedreferenceAlmeshari K, Pall A, Chaballout A, et al. Targeted monitoring of donor‐specific HLA antibodies following renal transplantation. Clin Transplant 2011; 395 – 400.en_US
dc.identifier.citedreferenceLiefeldt L, Brakemeier S, Glander P, et al. Donor‐specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192 – 1198.en_US
dc.identifier.citedreferenceRostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor‐based regimens to a belatacept‐based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430 – 439.en_US
dc.identifier.citedreferencePestana JO, Grinyo JM, Vanrenterghem Y, et al. Three‐year outcomes from BENEFIT‐EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630 – 639.en_US
dc.identifier.citedreferenceVincenti F, Larsen CP, Alberu J, et al. Three‐year outcomes from BENEFIT, a randomized, active‐controlled, parallel‐group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210 – 217.en_US
dc.identifier.citedreferenceLarsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high‐affinity variant of CTLA4‐Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443 – 453.en_US
dc.identifier.citedreferenceLucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. Antibody‐mediated rejection in kidney transplantation: An update. Expert Opin Pharmacother 2011; 12: 579 – 592.en_US
dc.identifier.citedreferenceRoberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody‐mediated rejection in kidney transplant recipients: A systematic review. Transplantation 2012; 94: 775 – 783.en_US
dc.identifier.citedreferenceBöhmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d‐positive acute kidney allograft rejection: A randomized controlled trial. Am J Transplant 2007; 7: 117 – 121.en_US
dc.identifier.citedreferenceBlake P, Sutton D, Cardella CJ. Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res 1990; 337: 249 – 252.en_US
dc.identifier.citedreferenceBonomini V, Vangelista A, Frasca GM, Di Felice A, Liviano D'Arcangelo G. Effects of plasmapheresis in renal transplant rejection: A controlled study. Trans Am Soc Artif Intern Organs 1985; 31: 698 – 703.en_US
dc.identifier.citedreferenceKirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981; 32: 164 – 165.en_US
dc.identifier.citedreferenceAllen NH, Dyer P, Geoghegan T, Harris K, Lee HA, Slapak M. Plasma exchange in acute renal allograft rejection: A controlled trial. Transplantation 1983; 35: 425 – 428.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt12589.pdf
Size:
1.880MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.